The Ability of Quantitative, Specific, and Sensitive Point-of-Care/Chair-Side Oral Fluid Immunotests for aMMP-8 to Detect Periodontal and Peri-Implant Diseases by Alassiri, Saeed et al.
Review Article
The Ability of Quantitative, Specific, and Sensitive
Point-of-Care/Chair-Side Oral Fluid Immunotests for aMMP-8 to
Detect Periodontal and Peri-Implant Diseases
Saeed Alassiri,1 Pirjo Parnanen ,1 Nilminie Rathnayake,2 Gunnar Johannsen,2
Anna-Maria Heikkinen,1 Richard Lazzara,3 Peter van der Schoor,2,3
Jan Gerrit van der Schoor,3 Taina Tervahartiala,1 Dirk Gieselmann,3 and Timo Sorsa 1,2
1Department of Oral and Maxillofacial Diseases, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
2Department of Dental Medicine, Division of Periodontology, Karolinska Institutet, Stockholm, Sweden
3Institute of Molecular Dentistry, Solingen, Germany
Correspondence should be addressed to Timo Sorsa; timo.sorsa@helsinki.fi
Received 12 March 2018; Accepted 21 June 2018; Published 5 August 2018
Academic Editor: Waszkiewicz Napoleon
Copyright © 2018 Saeed Alassiri et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The analysis of the disease-specific oral and systemic biomarkers in saliva and oral fluids (i.e., mouth rinse, gingival crevicular fluid
(GCF), and peri-implantitis fluid (PISF)) is demanding. Several hosts and microbial factors may influence their expression, release,
and levels. The type of saliva/oral fluids utilized for the diagnostics affects the analysis. High sensitivity and specificities together
with sophisticated methods and techniques are essential for valuable outcome. We describe here recently developed practical,
convenient, inexpensive, noninvasive, and quantitative mouth rinse and PISF/GCF/chair-side/point-of-care (PoC) lateral-flow
aMMP-8 immunoassays (PerioSafe and ImplantSafe/ORALyser) to detect, predict, and monitor successfully the course,
treatment, and prevention of periodontitis and peri-implantitis, respectively. The tests have been independently and successfully
validated to differentiate periodontal and peri-implant health and disease in Finland, Germany, Netherland, Sweden, Turkey,
Nigeria, Malawi, and USA. The clinical use of salivary/oral fluid biomarkers to identify oral and systemic conditions requires
additional studies utilizing these noninvasive screening, diagnostic, and preventive aMMP-8 PoC/chair-side technologies.
1. Introduction
Diagnosis of periodontal and peri-implant diseases are
mostly based on an array of clinical measurements and indi-
ces including pocket probing depths, bleeding on probing,
and assessment of clinical attachment level together with
radiographic findings. Additional information such as medi-
cal, hereditary, and specific features and the amount of dental
plaque have also been recorded [1, 2]. These laborous diag-
nostic procedures require not only multiple manual record-
ings but also professional examiners with trained expertise.
So far, these clinical and radiographic diagnostic procedures
are the best currently available ones for diagnosing and mon-
itoring the disease course, treatment, and maintenance [1].
However, they can only assess the past experience, current
extent, and severity of the periodontal and peri-implant
diseases. Since these clinical and radiographic analyses of
periodontitis and peri-implantitis have low sensitivity and
low positive predictive value [1], no reliable information
can be obtained regarding the diseases’ current activities
and their future courses [1]. Also, the episodic progression
of periodontitis and peri-implantitis makes the accurate
assessment of disease activity and progression difficult and
complicated [1]. Neutrophil collagenase, also called matrix
metalloproteinase (MMP)-8, polymorphonuclear (PMN)
leukocyte collagenase, or collagenase-2, has been identified
and characterized as a major collagenolytic enzyme that
causes active periodontal and peri-implant degeneration
(APD) in periodontitis and peri-implantitis [3–7]. MMP-8
can resolve and regulate inflammatory and immunological
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cascades by processing nonmatrix bioactive substrates such
as chemokines, cytokines, serpins, and complement com-
ponents. Physiological levels of MMP-8 can exert protec-
tive and defensive anti-inflammatory characteristics [5].
Increased levels of especially active MMP-8 (aMMP-8),
but not latent, inactive proform, have been found in peri-
odontitis- and peri-implantitis-affected oral fluids (saliva,
mouth rinse, gingival crevicular fluid (GCF), and peri-
implant sulcular fluid (PISF)) [8–10]. A key characteristic
of active periodontal and peri-implant diseases is the sus-
tained pathological elevation and activation of MMP-8 in
periodontal and peri-implant tissues, which are reflected
in oral fluids [4]. Consequently, aMMP-8 is a promising
biomarker candidate for diagnosing and assessing the pro-
gression and course of these episodic oral inflammatory tis-
sue destructive and degenerative diseases [3, 4]. More
importantly, aMMP-8 in oral fluids can also serve as a pre-
dictive and preventive adjunctive biotechnological tool to
indicate [4, 7, 8, 11] and time the preventive interventions
(secondary prevention or supportive periodontal/peri-
implant therapy [12, 13]) and to inhibit or reduce the
conversion of preperiodontitis (formerly gingivitis) and
preperi-implantitis (formerly mucositis) to periodontitis
and implantitis, respectively.
With this background, we describe the documentation of
currently commercially available quantitative reader-based
aMMP-8 oral fluid specific point-of-care/chair-side lateral-
flow reader-equipped immunotests, that is, PerioSafe and
ImplantSafe/ORALyser, for periodontal and peri-implant
diseases, respectively.
2. PerioSafe and ImplantSafe, aMMP-8 Oral
Fluid PoC/Chair-Side Tests, in Chronic
Periodontitis and Peri-Implantitis:
Diagnostic Utilizations and Monitoring the
Effects of Treatments
Recently, lateral-flow point-of-care (PoC)/chair-side tests
(PerioSafe and ImplantSafe), discovered in Finland and fur-
ther developed in Germany [4, 14], have been developed
based on earlier described technologies and monoclonal anti-
bodies [4, 5, 14, 15]. The tests, PerioSafe and ImplantSafe,
and reader (ORALyser) have been developed and manufac-
tured by Medix Biochemica Ltd (Espoo, Finland) and den-
tognostics GmbH (Jena, Germany) and are commercially
available from Dentognostics GmbH (Jena, Germany). In
fact, the PoC/chair-side aMMP-8 lateral-flow immunotests
resemble the classical pregnancy and/or recently described
HIV-PoC tests [16, 17]. The aMMP-8 oral fluid tests can
be used according to the manufacturer’s instructions [5].
PerioSafe measures and analyses the levels of aMMP-8 in
mouth rinse and ImplantSafe in PISF and GCF; thus, Peri-
oSafe is patient-specific and ImplantSafe is site-specific [5,
14]. PerioSafe and ImplantSafe test-sticks can be quanti-
tated by the ORALyser reader in 5min PoC/chair-side
[4]. PerioSafe and ImplantSafe with ORALyser quantita-
tion are reliable, quantitative, noninvasive, safe, and inex-
pensive adjunctive point-of-care diagnostic tools for
diagnosis, screening, monitoring, and prevention of peri-
odontal and peri-implant diseases [4, 5].
Chronic periodontitis (n = 10), peri-implantitis (n = 30),
and their healthy controls (n = 10 and 30, resp.) were charac-
terized clinically and from X-rays as described earlier [11, 15,
18, 19]. Ten clinically and X-ray-diagnosed adult chronic
periodontitis patients [11, 15] were all (100%) diagnosed to
be aMMP-8 positive by PerioSafe visual test, and their
aMMP-8 lateral-flow test-sticks were quantitated by ORALy-
ser before (all >20 ng/ml, visually (+)) and after periodontal
treatment, scaling and root planing (SRP) or anti-infective
treatment (Figures 1(a) and (b)). SRP or anti-infective treat-
ment was found to reduce the pocket depths and the bleeding
of probing [11, 15]. SRP also affected the aMMP-8 levels in
mouth rinse from positive (+) to negative (−) by visual esti-
mation of the test results and from >20ng/ml (positive (+))
to <20ng/ml (negative (−)) by ORALyser reader quantitation
(Figure 1(a)). Systemically and periodontally healthy dental
students (age 22–24, n = 10) served as healthy controls
(Figure 1(b)).
We further demonstrated here that the ImplantSafe
aMMP-8 PoC/chair-side sulcular fluid test site specifically
in 5min detects the peri-implantitis sites (n = 29) differ-
entiating them from clinically healthy peri-implant sites
(n = 32) and can be utilized for monitoring treatment
(Figures 2(a) and 2(b)). Peri-implantitis and healthy sites
were diagnosed clinically and by X-rays as described [18].
Peri-implantitis sites were surgically treated according to
the Swedish national guidelines [19]. We also analysed
quantitatively aMMP-8 by immunofluorometric assay
(IFMA) [15] and all forms of MMP-9 densitometrically by
quantitated gelatin-zymography [20]. Similar to ImplantSafe
PoC/chair-side findings, elevated aMMP-8 levels could be
detected by IFMA in all peri-implantitis sites (29 =100%
ImplantSafe-positive >20ng/ml (124,60 ±22.50ng/ml)) differ-
ing from clinically healthy sites all having low aMMP-8 levels
(32 sites/<20ng/ml (18.60±3.46ng/ml)) all being ImplantSafe
PoC-negative (Figure 2(b)). This difference was statistically
significant (p < 0 0001, Wilcoxon test) (Figure 2(a)). Surgical
treatment of peri-implantitis sites according to the Swedish
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Figure 1: aMMP-8 chair-side levels analysed visually (+/−) and
quantitated for aMMP-8 (ng/ml) by ORALyser reader to monitor
the effect of periodontal treatment (scaling and root planing) on
chronic periodontitis (n = 10) (a) and healthy controls (n = 10) (b).
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national guidelines [19] caused the positive ImplantSafe tests
to be negative (Figure 2(b)). This pilot case-control peri-
implantitis study shows both 100% sensitivity and specificity
for ImplantSafe test. Currently, this test is available also as a
reader-equipped/quantitated-PoC tool, that is, ORALyser
reader [4]. MMP-9 or gelatinase-B, analysis by gelatin zymo-
graphy from these same PISF samples, revealed that any form
of MMP-9 or total MMP-9 was not able to differentiate peri-
implant health and disease (Figure 2(a)). Our pilot case-
control studies have received approval from the local ethical
committee of Stockholm Community, Sweden (2016-08-24/
2016/1:8 and 2016-1-24) and the Helsinki University Central
Hospital, Finland (nro260/13/03/00/13).
3. Discussion
Currently, the practical and quantitative PoC/chair-side
lateral-flow oral fluid aMMP-8 immunoassays have been
successfully developed and are commercially available. The
tests have been independently and successfully validated
in Finland, Nigeria, Germany, Holland, Malawi, Turkey,
Sweden, and USA [4, 5, 14, 21–24]. The tests have diagnostic
sensitivity and specificity 76–90% and 96%, respectively,
corresponding to odds ratio of >72 [4, 5, 14, 21]. The
test results are quantitatively available by the reader in
5min PoC/chair-side [4]. The tests have been shown to
be useful to screen susceptible sites and patients, differen-
tiate active and inactive periodontitis and peri-implantitis
sites, predict the future disease progression, and monitor
the treatment—with or without different adjunctive
medications—response, and maintenance therapy [4, 5].
As demonstrated in the present study, the tests excellently dif-
ferentiated periodontal and peri-implant health and diseases.
Additionally, the test can identify initial and alarm or early
periodontitis (preperiodontitis) in genetically predisposed
adolescents [21]. Thus, the test is effective in both adult and
adolescent populations and can act in “a gene”-test manner
[14, 21]. Pathologically elevated aMMP-8 associates, reflects,
and precedes the active phase of periodontal and peri-
implant diseases, that is, APD [4, 7, 8]. This forms the basis
of predictive value for aMMP-8 oral fluid tests in periodontal
and peri-implant diseases; thus, the test is positive ahead or
before clinical manifestations and/or radiographic outcomes
of APD [4, 5, 8]. The tests can detect enough early subclinical
and silent developing preperiodontitis and preperi-
implantitis [4, 21]. The tests are very suitable for monitoring
the disease’s development and progression as well as timing
and targeting the preventive and therapeutic interventions
(i.e., secondary prevention and/or supportive periodontal/
peri-implant therapy) [12, 13]. In comparison to bleeding
on probing, aMMP-8 PoC/chair-side test is much more
sensitive to distinguish periodontal health and disease
[14]. Noteworthy, bleeding on probing always causes bac-
teraemia. Noninvasive PerioSafe and ImplantSafe testings
never cause bacteraemia.
Regarding other PoC technologies for periodontitis and
peri-implantitis, Ritzer et al. [25] described peri-implantitis/
periodontitis online diagnosis utilizing elegantly the tongue
as a 24/7 detector allowing diagnosis by “anyone, anywhere,
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Figure 2: Peri-implant sulcular fluid (PISF) collected from 29 peri-implantitis and 32 periodontally healthy sites were tested for elevated
aMMP-8 by ImplantSafe PoC/chair-side test (+/−), analysed for aMMP-8 (ng/ml) by immunofluorometric assay (IFMA), and by
quantitated gelatin zymography for all molecular weight forms of gelatinase-B (MMP-9, zymographic densitometric units) (a). Implantitis
sites were tested before and after surgical treatment by ImplantSafe (+/−); treatment caused positive sites to be negative (b). Elevated
aMMP-8 levels in PISF detected by ImplantSafe positivity and IFMA associated significantly with peri-implantitis (p < 0 0001, Wilcoxon
test (∗∗∗)) and could thus be conveniently PoC detected in 5min by ImplantSafe. Any forms or total MMP-9 did –not differentiate
peri-implantitis and healthy sites (a).
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gum-containing peptide sensors as protease cleavable linkers
between a bitter taste substance and a microparticle. MMPs
upregulated in oral cavity and fluids (i.e., saliva and GCF/
PISF) are presented to be responsible for cleaving the sensor
in chewing gum generating the bitter taste consequently to
be detected by the tongue as a 24/7 in vivo and online
sensor [25]. Nonetheless, their elegant 24/7 tongue sensor
assay is not MMP-specific for the main collagenolytic
MMP, MMP-8, upregulated and activated in periodontitis-
and peri-implantitis-affected periodontal and peri-implant
tissue, gingiva and oral fluids, including saliva, GCF, PISF,
and mouth rinse. The sensor is sensitive also to cleavages
by MMP-1, MMP-13, and MMP-9 present and upregulated
in the diseased periodontitis and peri-implantitis tissue and
oral fluids [25]. Furthermore, no information was provided
regarding specificity, sensitivity, and predictability of the
24/7 tongue technology regarding periodontitis and peri-
implantitis. PerioSafe and ImplantSafe exert 76–90% speci-
ficity and >96% sensitivity [4, 5]. Also, the susceptibilities
of the protease cleavable linker 24/7 sensor to catalytically
competent and effective microbial proteases expressed and
released by dysbiotic oral periodontopathogens and candidial
species were not addressed [26, 27]. Recently, a PoC/chair-
side device, comparable to PCR-detection, for Porphyromo-
nas gingivalis related to chronic periodontitis detection has
been developed [28]. A chair-side assay for GCF calprotectin
has been described [29]. Calprotectin does not degrade
anything [29].
PerioSafe and ImplantSafe are specific and sensitive for
aMMP-8, a major destructive and collagenolytic factor for
APD [4, 5]. Overall, PerioSafe and ImplantSafe, aMMP-8
quantitative oral fluid PoC/chair-side lateral-flow immunot-
ests, are the first clinically validated commercially available
diagnostic, prognostic, quantitative, predictive, noninvasive,
and preventive PoC/chair-side technologies for periodontal
and peri-implant diseases [4, 5]; the tests can be used by
dental and medical professionals linking these disciplines
[4]. Potentially, such aMMP-8 PoC tests can eventually be
adapted for other medical disciplines [30, 31].
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